Morinda Officinalis Oligosaccharides Alleviate Cognitive Dysfunction Through Depressing Β-Amyloid Deposition and ER Stress in Alzheimer'S Disease

tingting xu,Ting-Ting Xu,Zheng-Yun Han,Yong-Hui Dou,Bei-Yin Shi,Yue Shu,Jie Yang,Yao-Yu Wang,Jie-Ying Chen,Shuiqing Huang
DOI: https://doi.org/10.2139/ssrn.4052315
2022-01-01
SSRN Electronic Journal
Abstract:Alzheimer’s disease (AD), the leading cause of dementia, is characterized of the abnormal accumulation of amyloid-β (Aβ) plaques, neuronal atrophy and synapse loss. Morinda officinalis oligosaccharides (MOOs) have been reported to have neuroprotective effect and AD therapeutic potential. However, the mechanism is still unclear. In this study, we developed experiments on APP/PS1 mice and Aβ-treated SH-SY5Y neuroblastoma cells to validate our prediction. Behavioral test showed that MOOs ameliorated cognitive dysfunction. MOOs decreased Aβ deposition, inhibited neural apoptosis, elevated neurotrophic factors in APP/PS1 mice. Furthermore, The ER stress indicators, phosphorylation of PERK and IRE-1α, were also inhibited by MOOs. Taken together, this study uncovers the mechanism-of-actions of new therapeutics for AD and has identified MOOs could ameliorate AD pathology by inhibiting Aβ deposition, neuron apoptosis, and ER stress.
What problem does this paper attempt to address?